Standard BioTools
LAB
69 hedge funds and large institutions have $89.9M invested in Standard BioTools in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 12 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
66% more capital invested
Capital invested by funds: $54.2M → $89.9M (+$35.6M)
1% more funds holding
Funds holding: 68 → 69 (+1)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0.32% less ownership
Funds ownership: 58.62% → 58.31% (-0.32%)
91% less call options, than puts
Call options by funds: $22K | Put options by funds: $255K
Top Buyers
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$1.06M |
| 2 |
SAM
Silverback Asset Management
Chapel Hill,
North Carolina
|
+$790K |
| 3 |
Jane Street
New York
|
+$372K |
| 4 |
Neuberger Berman Group
New York
|
+$308K |
| 5 |
Morgan Stanley
New York
|
+$279K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
76
Virtu Financial
New York
| – | -$19K | -16,167 | Closed |
|
|
IA
77
IFP Advisors
Tampa,
Florida
| – | -$9K | -1,527 | Closed |
|
|
RFS
78
Retirement Financial Solutions
Knoxville,
Tennessee
| – | -$373 | -319 | Closed |
|
|
MCC
79
Money Concepts Capital
Palm Beach Gardens,
Florida
| – | -$117 | -100 | Closed |
|
80
Citigroup
New York
| – | -$71 | -61 | Closed |
|
LAB Hedge Fund Activity: Q1 2023 in Review
69 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q1 2023, worth a combined $89.9M — up 66% from $54.2M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new LAB positions and 12 closed out — a net gain of 1 holder — while 17 added to existing stakes and 16 trimmed.
The largest buyer was HighTower Advisors, adding an estimated $1.06M. The largest seller was Needham Investment Management, cutting an estimated $1.83M.
- 69 institutional investors held Standard BioTools (LAB) as of Q1 2023, up from 68 in Q4 2022.
- Funds reported $89.9M of Standard BioTools stock for Q1 2023, up 66% quarter-over-quarter.
- 13 funds opened new Standard BioTools positions in Q1 2023 and 12 closed out, a net change of +1 holder.
- The largest Standard BioTools buyer in Q1 2023 was HighTower Advisors, an estimated $1.06M added.
- The largest Standard BioTools seller in Q1 2023 was Needham Investment Management, an estimated $1.83M sold.
Based on aggregated 13F filings for Q1 2023.